Ruxolitinib combined with prednisone, thalidomide and danazol for treatment of myelofibrosis: a pilot study.
10.3760/cma.j.issn.0253-2727.2019.01.005
- Author:
Ze Feng XU
1
;
Tie Jun QIN
;
Hong Li ZHANG
;
Li Wei FANG
;
Li Juan PAN
;
Nai Bo HU
;
Shi Qiang QU
;
Bing LI
;
Zhi Jian XIAO
Author Information
1. Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, The State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
- Publication Type:Journal Article
- Keywords:
Danazol;
Prednisone;
Primary myelofibrosis;
Ruxolitinib;
Thalidomide
- MeSH:
Danazol;
Drug Combinations;
Humans;
Nitriles;
Pilot Projects;
Prednisone;
Primary Myelofibrosis/drug therapy*;
Pyrazoles/therapeutic use*;
Pyrimidines;
Thalidomide/therapeutic use*;
Treatment Outcome
- From:
Chinese Journal of Hematology
2019;40(1):24-28
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the efficacy and tolerability of ruxolitinib combined with prednisone, thalidomide and danazol for treatment of in myelofibrosis (MF). Methods: Patients of MF according to the WHO 2016 criteria, received ruxolitinib (RUX) combined with prednisone, thalidomide and danazol (PTD). The response, changes of blood counts and adverse events were evaluated. Results: Six PMF and one post-ET MF patients were enrolled. Four patients presented JAK2V617F mutation, one CALR mutation, one MPL mutation, one triple-negative. Responses per IWG-MRT criteria were clinical improvement in 5 patients, stable disease in 2 ones, spleen response in 6 ones. All of 7 patients were symptomatic responses, four patients achieved at least 50% improvement from baseline on MPN-SAF TSS. Three patients initially treated with RUX alone, all of 3 patients experienced treatment-associated anemia and thrombocytopenia. Then these 3 patients received RUX combined with PTD, both hemoglobin and platelet increased significantly. Four patients initially treated with RUX combined with PTD. Increased levels of hemoglobin and platelet were seen in all of 7 patients received RUX combined with PTD with maximum increased hemoglobin of 30(18-54) g/L and maximum increased platelets of 116(13-369)×10(9)/L, respectively from baseline. The treatment dose of RUX increased due to improved platelet count in 3 patients. The frequent non-hematologic adverse events grade 1-2 were constipation, abdominal distension, crura edema and increased ALT. Conclusions: RUX combined with PTD for treatment of MF may modulate initial hematologic toxicity observed when RUX alone, and may increase response due to improved levels of hemoglobin or platelet.
